Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in Curr Opin Urol Retrieve available abstracts of 71 articles: HTML format

Single Articles

April 2024
1. ERTL I, Shariat SF, Berger W, Englinger B, et al
   Preclinical models for bladder cancer therapy research.
   Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
   PubMed     Abstract available
   
   
   
2. ENGLINGER B
   Molecular research in bladder cancer.
   Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
   PubMed    
   
   
   
3. NOSSING C, Herek P, Shariat SF, Berger W, et al
   Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
   Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
   PubMed     Abstract available
   
   
   
4. ABUFARAJ M, Al Karmi J, Bdeir A
   Is there a role for metastasis-directed therapy in bladder cancer?
   Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
   PubMed     Abstract available
   
   
   March 2024
5. CALLERIS G, von Deimling M, Kesch C, Soria F, et al
   Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
   Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
   PubMed     Abstract available
   
   
   January 2024
6. GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
   AI-powered radiomics: revolutionizing detection of urologic malignancies.
   Curr Opin Urol. 2024;34:1-7.
   PubMed     Abstract available
   
   
   
7. IKEDA A, Nosato H
   Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
   Curr Opin Urol. 2024;34:27-31.
   PubMed     Abstract available
   
   
   November 2023
8. CANCEL-TASSIN G, Koutros S
   Use of genomic markers to improve epidemiologic and clinical research in urology.
   Curr Opin Urol. 2023;33:414-420.
   PubMed     Abstract available
   
   
   July 2023
9. DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
   Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
   Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
   PubMed     Abstract available
   
   
   
10. YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
    Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
    Curr Opin Urol. 2023;33:258-268.
    PubMed     Abstract available
    
    
    June 2023
11. MELLEMA JJ, van Rhijn BWG, van der Heijden MS
    Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
    PubMed     Abstract available
    
    
    May 2023
12. KRAJEWSKI W, Laszkiewicz J, Nowak L, Szydelko T, et al
    Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review.
    Curr Opin Urol. 2023;33:230-238.
    PubMed     Abstract available
    
    
    April 2023
13. KATIMS AB, Bochner BH
    Extended pelvic lymph node dissection in muscle invasive bladder cancer.
    Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
    PubMed     Abstract available
    
    
    March 2023
14. MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
    PET in bladder cancer imaging.
    Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
    PubMed     Abstract available
    
    
    
15. BERNDL F, Frerichmann J, Berndl T
    Prevention and management of urinary tract infections after cystectomy.
    Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
    PubMed     Abstract available
    
    
    
16. WALZ S, Aslani V, Sawodny O, Stenzl A, et al
    Robotic radical cystectomy - more precision needed?
    Curr Opin Urol. 2023;33:157-162.
    PubMed     Abstract available
    
    
    
17. TONIN E, Shariat SF, Schiavina R, Brunocilla E, et al
    En-bloc resection of non-muscle invasive bladder cancer: does it really make a difference?
    Curr Opin Urol. 2023;33:147-151.
    PubMed     Abstract available
    
    
    January 2023
18. HORNAK J, Brisuda A, Babjuk M
    Transurethral resection of bladder cancer with or without fluorescence.
    Curr Opin Urol. 2023 Jan 12. doi: 10.1097/MOU.0000000000001071.
    PubMed     Abstract available
    
    
    December 2022
19. KAWADA T, Yanagisawa T, Araki M, Pradere B, et al
    Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
    Curr Opin Urol. 2022 Dec 12. doi: 10.1097/MOU.0000000000001065.
    PubMed     Abstract available
    
    
    November 2022
20. IBILIBOR C, Kennady EH, Greene KL
    The role of surgery for locally advanced urothelial cancers.
    Curr Opin Urol. 2022;32:614-617.
    PubMed     Abstract available
    
    
    September 2022
21. CROCEROSSA F, Autorino R, Carbonara U, Cantiello F, et al
    Extent of lymph node dissection and impact on survival in radical cystectomy for advanced bladder cancer.
    Curr Opin Urol. 2022 Sep 14. pii: 00042307-990000000-00040.
    PubMed     Abstract available
    
    
    
22. ESCOTT M, Avulova S, Bree KK, Westerman ME, et al
    Radical cystectomy and women's sexual health - can we do better?
    Curr Opin Urol. 2022;32:545-553.
    PubMed     Abstract available
    
    
    
23. PIJPERS OM, de Jong JJ, Zuiverloon TCM, Boormans JL, et al
    RNA-based urinary assays for non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022;32:523-530.
    PubMed     Abstract available
    
    
    
24. COMPERAT E, Oszwald A, Wasinger G, Klager J, et al
    Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.
    Curr Opin Urol. 2022;32:451-455.
    PubMed     Abstract available
    
    
    
25. LAUKHTINA E, Pradere B, Lemberger U, Karakiewicz PI, et al
    Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Curr Opin Urol. 2022;32:561-566.
    PubMed     Abstract available
    
    
    
26. SHEYBAEE MOGHADDAM F, Ghoreifi A, Djaladat H
    Comparative performance of the different orthotopic urinary diversions.
    Curr Opin Urol. 2022;32:554-560.
    PubMed     Abstract available
    
    
    
27. KIM SH, Lerner SP
    Drug instillation in the management of urinary tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:531-535.
    PubMed     Abstract available
    
    
    
28. MARTINI A, Fallara G, Ploussard G, Pradere B, et al
    Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma.
    Curr Opin Urol. 2022;32:500-503.
    PubMed     Abstract available
    
    
    
29. COMPERAT E, Wasinger G, Oszwald A, Shariat SF, et al
    Brief update of the new WHO classification for urothelial carcinoma.
    Curr Opin Urol. 2022;32:511-516.
    PubMed     Abstract available
    
    
    
30. MESSINA E, Pisciotti ML, Pecoraro M, Borrelli A, et al
    The use of MRI in urothelial carcinoma.
    Curr Opin Urol. 2022;32:536-544.
    PubMed     Abstract available
    
    
    July 2022
31. VON DEIMLING M, Pallauf M, Bianchi A, Laukhtina E, et al
    Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?
    Curr Opin Urol. 2022 Jul 25. pii: 00042307-990000000-00032.
    PubMed     Abstract available
    
    
    
32. LONATI C, Simeone C, Suardi N, Briganti A, et al
    Micropapillary bladder cancer: an evolving biology.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00030.
    PubMed     Abstract available
    
    
    
33. SCHOBER JP, Plimack E, Geynisman D, Zibelman M, et al
    The past, present, and future of pT0 in bladder cancer clinical trials.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00026.
    PubMed     Abstract available
    
    
    
34. SORIA F, Dutto D, Gontero P
    Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022 Jul 15. pii: 00042307-990000000-00019.
    PubMed     Abstract available
    
    
    
35. COMPERAT E, Wasinger G, Oszwald A, Pradere B, et al
    Nonmuscle-invasive bladder cancer, old problems, new insights.
    Curr Opin Urol. 2022;32:352-357.
    PubMed     Abstract available
    
    
    June 2022
36. VARTOLOMEI MD, Ferro M, Roth B, Teoh JY, et al
    Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
    Curr Opin Urol. 2022 Jun 27. pii: 00042307-990000000-00015.
    PubMed     Abstract available
    
    
    January 2022
37. REGNIER S, Califano G, Elalouf V, Albisinni S, et al
    Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review.
    Curr Opin Urol. 2022;32:54-60.
    PubMed     Abstract available
    
    
    
38. HUSSEIN AA, Li Q, Guru KA
    Robot-assisted radical cystectomy: surgical technique, perioperative and oncologic outcomes.
    Curr Opin Urol. 2022;32:116-122.
    PubMed     Abstract available
    
    
    
39. BERNDL F, Hassler MR
    Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Curr Opin Urol. 2022;32:48-53.
    PubMed     Abstract available
    
    
    
40. LONATI C, Moschini M, Simeone C, Spiess PE, et al
    Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:40-47.
    PubMed     Abstract available
    
    
    December 2021
41. ENIKEEV D, Babjuk M, Shpikina A, Shariat S, et al
    En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser.
    Curr Opin Urol. 2021 Dec 24. pii: 00042307-900000000-98808.
    PubMed     Abstract available
    
    
    November 2021
42. CICIONE A, Lombardo R, D'Annunzio S, De Nunzio C, et al
    Success factors for abdominal wall diversions, including ureterocutaneostomy.
    Curr Opin Urol. 2021;31:544-549.
    PubMed     Abstract available
    
    
    
43. HEESAKKERS JPFA, Witjes F
    Editorial: Medical, technical and functional aspect of various types of urinary diversion.
    Curr Opin Urol. 2021;31:542-543.
    PubMed    
    
    
    
44. GRAUER R, Wiklund NP
    Update on robotic cystectomy.
    Curr Opin Urol. 2021;31:537-541.
    PubMed     Abstract available
    
    
    
45. LIEDBERG F, Bobjer J
    Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
    Curr Opin Urol. 2021;31:556-561.
    PubMed     Abstract available
    
    
    
46. NUIJENS ST, Cobussen-Boekhorst H, Heesakkers JPFA, Witjes JA, et al
    Patient-reported outcomes and health-related quality of life after urinary diversions.
    Curr Opin Urol. 2021;31:574-579.
    PubMed     Abstract available
    
    
    
47. VAN 'T HOF MEM, Bruins HM, van Roermund JGH
    Management of upper urinary tract problems after radical cystectomy for urothelial carcinoma: tips and tricks.
    Curr Opin Urol. 2021;31:570-573.
    PubMed     Abstract available
    
    
    July 2021
48. 
    Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?: Erratum.
    Curr Opin Urol. 2021;31:436.
    PubMed    
    
    
    June 2021
49. JANSSEN GWB, Ramkumar RR, Lee BH, van der Heijden AG, et al
    Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade.
    Curr Opin Urol. 2021 Jun 25. pii: 00042307-900000000-98856.
    PubMed     Abstract available
    
    
    May 2021
50. CHAN EO, Pradere B, Teoh JY
    The use of artificial intelligence for the diagnosis of bladder cancer: a review and perspectives.
    Curr Opin Urol. 2021 May 11. pii: 00042307-900000000-98866.
    PubMed     Abstract available
    
    
    
51. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98868.
    PubMed     Abstract available
    
    
    
52. SCHUETTFORT VM, Pradere B, Comperat E, Abufaraj M, et al
    Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98867.
    PubMed     Abstract available
    
    
    
53. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments.
    Curr Opin Urol. 2021 May 6. pii: 00042307-900000000-98874.
    PubMed     Abstract available
    
    
    
54. PACKIAM VT, Richards J, Schmautz M, Heidenreich A, et al
    The current landscape of salvage therapies for patients with bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2021;31:178-187.
    PubMed     Abstract available
    
    
    
55. ABUFARAJ M, Al-Ani A, AlQudah A, Shariat SF, et al
    Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis.
    Curr Opin Urol. 2021;31:220-225.
    PubMed     Abstract available
    
    
    April 2021
56. PINAR U, Pradere B, Roupret M
    Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine.
    Curr Opin Urol. 2021 Apr 20. pii: 00042307-900000000-98882.
    PubMed     Abstract available
    
    
    December 2020
57. HUGAR LA, Gilbert SM, Sexton WJ, Kamat AM, et al
    Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020;Publish Ahead of Print.
    PubMed     Abstract available
    
    
    September 2020
58. SARI MOTLAGH R, Mori K, Aydh A, Karakiewicz PI, et al
    Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy.
    Curr Opin Urol. 2020;30:701-710.
    PubMed     Abstract available
    
    
    
59. REBHAN K, Ertl IE, Shariat SF, Grollman AP, et al
    Aristolochic acid and its effect on different cancers in uro-oncology.
    Curr Opin Urol. 2020;30:689-695.
    PubMed     Abstract available
    
    
    July 2020
60. ERTL IE, Shariat SF, Mostafaei H, Ilijazi D, et al
    Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Curr Opin Urol. 2020;30:557-565.
    PubMed     Abstract available
    
    
    
61. BRONIMANN S, Lemberger U, Bruchbacher A, Shariat SF, et al
    Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    Curr Opin Urol. 2020;30:519-526.
    PubMed     Abstract available
    
    
    
62. LIU B, Welk B
    Urological malignancies in neurogenic patients.
    Curr Opin Urol. 2020;30:501-506.
    PubMed     Abstract available
    
    
    May 2020
63. PRADERE B, Schuettfort V, Mori K, Quhal F, et al
    Management of de-novo urothelial carcinoma in transplanted patients.
    Curr Opin Urol. 2020;30:467-474.
    PubMed     Abstract available
    
    
    
64. JAHRREISS V, Pradere B, Laukhtina E, Mori K, et al
    Catalog of exogenous risk factors for bladder carcinogenesis.
    Curr Opin Urol. 2020;30:449-456.
    PubMed     Abstract available
    
    
    
65. CARANDO R, Shariat SF, Moschini M, D'Andrea D, et al
    Ureteral and urethral recurrence after radical cystectomy: a systematic review.
    Curr Opin Urol. 2020;30:441-448.
    PubMed     Abstract available
    
    
    
66. KHETRAPAL P, Conroy S, Kelly JD, Catto JWF, et al
    Comparing open-radical cystectomy and robot-assisted radical cystectomy: current status and analysis of the evidence.
    Curr Opin Urol. 2020;30:400-406.
    PubMed     Abstract available
    
    
    
67. SUBIELA JD, Rodriguez Faba O, Guerrero-Ramos F, Aumatell J, et al
    Carcinoma in situ of the bladder: why is it underdetected?
    Curr Opin Urol. 2020;30:392-399.
    PubMed     Abstract available
    
    
    
68. SORIA F, Giordano A, Gontero P
    Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?
    Curr Opin Urol. 2020;30:370-376.
    PubMed     Abstract available
    
    
    
69. TERRITO A, Bevilacqua G, Meneghetti I, Mercade A, et al
    En bloc resection of bladder tumors: indications, techniques, and future directions.
    Curr Opin Urol. 2020;30:421-427.
    PubMed     Abstract available
    
    
    
70. LOTAN Y
    Novel technologies that change the diagnostic and treatment paradigm in urology: standard turbt remains the standard.
    Curr Opin Urol. 2020;30:477-478.
    PubMed    
    
    
    
71. ALMASSI N, Bochner BH
    Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use.
    Curr Opin Urol. 2020;30:415-420.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.